Associations of metabolic syndrome and C‐reactive protein with mortality from total cancer, obesity‐linked cancers and breast cancer among women in <scp>NHANES III</scp>

Gathirua-Mwangi, Wambui G.; Song, Yiqing; Monahan, Patrick O.; Champion, Victoria L.; Zollinger, Terrell W.

doi:10.1002/ijc.31344

Cited by 36 publications

(32 citation statements)

References 48 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are consistent with those from previous studies [24,25,29,30]. In a cohort of 4,216 eBC patients, the presence of MetS at diagnosis was associated with a 1.5-fold increased risk of recurrence or second primary BC and 1.65-fold increased risk of BC-specific mortality compared with patients with no MetS [24].…”

Section: Discussionsupporting

confidence: 92%

“…In a cohort of 4,216 eBC patients, the presence of MetS at diagnosis was associated with a 1.5-fold increased risk of recurrence or second primary BC and 1.65-fold increased risk of BC-specific mortality compared with patients with no MetS [24]. Similarly, a study in 10,014 patients reported twofold increase in BC mortality with MetS [30], while another study (N = 288,834) reported a 23% higher risk of BC mortality in only older (> 60 years) women with MetS without any impact in younger patients [25]. Interestingly, MetS also correlated with an enhanced risk of new BC events (defined as loco-regional recurrences, distant metastasis or new primary BC) in a prospective study using 2,092 eBC patients; however, an impact on survival was not evaluated [29].…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

Buono

Crispo

Giuliano

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Obesity and insulin resistance have been associated with poor prognosis in breast cancer (BC). The present prospective study aimed to investigate the impact of metabolic syndrome (MetS) and its components on early BC (eBC) patients' outcome. Methods MetS was defined by the presence of 3 to 5 of the following components: waist circumference > 88 cm, blood pressure ≥ 130/≥ 85 mmHg, serum levels of triglycerides ≥ 150 mg/dL, high density lipoprotein < 50 mg/dL and fasting glucose ≥ 110 mg/dL. Seven hundred and seventeen patients with data on ≥ 4 MetS components at BC diagnosis were enrolled. Study population was divided into two groups: patients with < 3 (non-MetS) vs. ≥ 3 components (MetS). Categorical variables were analyzed by Chi-square test and survival data by log-rank test and Cox proportional hazards regression model. Results Overall, 544 (75.9%) and 173 (24.1%) women were categorized as non-MetS and MetS, respectively. MetS patients were more likely to be older, postmenopausal, and insulin-resistant compared to non-MetS patients (p < 0.05). In multivariate analysis, MetS patients had a numerically higher risk of relapse [disease-free survival (DFS), hazard ratio (HR) 1.51, p = 0.07] and a significantly higher risk of death compared to non-MetS patients [overall survival (OS), HR 3.01, p < 0.0001; breast cancer-specific survival (BCSS), HR 3.16, p = 0.001]. Additionally, patients with 1 to 2 components of MetS had an increased risk of dying compared to patients with 0 components (OS, HR 4.90, p = 0.01; BCSS, HR 6.07, p = 0.02). Conclusions MetS correlated with poor outcome in eBC patients. Among patients without full criteria for MetS diagnosis, the presence of 1 or 2 components of the syndrome may predict for worse survival.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 92%

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

Buono

Crispo

Giuliano

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…; Gathirua‐Mwangi et al. ). On the other hand, exercise inhibits inflammation in adipose tissue and creates unfavorable conditions for cancer, (Dieli‐Conwright et al.…”

Section: Discussionmentioning

confidence: 98%

“…; Gathirua‐Mwangi et al. ; Guo et al. ) and it has been hypothesized that this may be due to a mild proinflammatory state and attenuated immune response (Khan et al.…”

Section: Discussionmentioning

confidence: 99%

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy

et al. 2019

View full text Add to dashboard Cite

Women with early‐stage breast cancer have reduced peak exercise oxygen uptake (peak VO2). The purpose of this study was to evaluate peak VO2 and right (RV) and left (LV) ventricular function prior to adjuvant chemotherapy. Twenty‐nine early‐stage breast cancer patients (mean age: 48 years) and 10 age‐matched healthy women were studied. Participants performed an upright cycle exercise test with expired gas analysis to measure peak VO2. RV and LV volumes and function were measured at rest, submaximal and peak supine cycle exercise using cardiac magnetic resonance imaging. Peak VO2 was significantly lower in breast cancer patients versus controls (1.7 ± 0.4 vs. 2.3 ± 0.5 L/min, P = 0.0013; 25 ± 6 vs. 35 ± 6 mL/kg/min, P = 0.00009). No significant difference was found between groups for peak upright exercise heart rate (174 ± 13 vs. 169 ± 16 bpm, P = 0.39). Rest, submaximal and peak exercise RV and LV end‐diastolic and end‐systolic volume index, stroke index, and cardiac index were significantly lower in breast cancer patients versus controls (P < 0.05 for all). No significant difference was found between groups for rest and exercise RV and LV ejection fraction. Despite preserved RV and LV ejection fraction, the decreased peak VO2 in early‐stage breast cancer patients prior to adjuvant chemotherapy is due in part to decreased peak cardiac index secondary to reductions in RV and LV end‐diastolic volumes.

show abstract

“…suggested that higher baseline fasting serum concentrations of glucose, insulin, and insulin resistance were all independently associated with pancreatic cancer after adjusting for age, smoking and body mass index 42. These reports were in line with the independent effects of WC and fasting level of glucose for pancreatic cancer development found in our study.A disturbed inflammatory status might play an important role in mediating the putative tumorigenesis of MetS 43. In the present study,the HRs increased when MetS and CRP were jointly (MetS / CRP ≥1.00 mg/dL, HR = 1.55) assessed for risk of pancreatic cancer compared to when MetS was assessed alone (MetS / CRP < 1.00 mg/dL, HR = 1.44) or CRP was assessed alone (No MetS / CRP ≥1.00 mg/dL, HR = 1.19).…”

mentioning

confidence: 99%

Metabolic syndrome and risk of pancreatic cancer: A population‐based prospective cohort study

Xia

Pan

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Metabolic syndrome (MetS) and its components may link to pancreatic cancer risk; however, current epidemiological evidence is limited, and the potential mechanisms underlying the associations remain unclear. To investigate this, we carried out this prospective cohort study of 474 929 participants without a diagnosis of cancer based on UK Biobank dataset. MetS was defined according to the International Diabetes Federation criteria and pancreatic cancer was identified through linkage to UK cancer registries (median follow-up time: 6.6 years). We evaluated hazard ratio (HR) and 95% confidence interval (CI) with Cox proportional hazards regression, adjusting for demography and lifestyle factors. Restricted cubic spline was performed for each MetS component to investigate their possible nonlinear associations with risk of pancreatic cancer. During 3 112 566 person-years of follow-up, 565 cases of pancreatic cancer were identified. Individuals with MetS (HR = 1.31, 95% CI, 1.09-1.56), central obesity (HR = 1.24, 95% CI, 1.02-1.50) and hyperglycemia (HR = 1.60, 95% CI, 1.31-1.97) had increased risk of pancreatic cancer. Higher waist circumference (WC) and blood glucose were independently associated with pancreatic cancer, with no evidence against nonlinearity. Although elevated CRP (≥1.00 mg/dL) showed a positive association with the risk for pancreatic cancer, the effect was substantially increased only in participants with MetS and CRP ≥1.00 mg/dL. Our study demonstrated a positive association between MetS and increased risk of pancreatic cancer, with two of the MetS components, WC and blood glucose, showing independent associations in linear manner. Our study also suggested a potential joint effect of MetS and CRP in pancreas tumorigenesis.

show abstract

Associations of metabolic syndrome and C‐reactive protein with mortality from total cancer, obesity‐linked cancers and breast cancer among women in NHANES III

Cited by 36 publications

References 48 publications

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy

Metabolic syndrome and risk of pancreatic cancer: A population‐based prospective cohort study

Contact Info

Product

Resources

About